GlobeNewswire by notified

PGS Completes Refinancing

Share

March17, 2023, Oslo, Norway: PGS ASA and/or its subsidiaries (“PGS” or the “Company”) has successfully placed a new $450 million senior secured bond with 4-year tenor (the “Bonds”). The proceeds from the Bonds will together with cash held on balance sheet be used to repay $600 million of the Company’s Term Loan B (the “TLB”) maturing in March 2024 at par value (the “Transaction”). The Transaction is expected to be completed around March 31, 2023.

The offshore seismic market is in strong recovery as multiple years of underinvestment in oil and gas exploration and development, combined with a materially changed energy security situation, drive a strong increase of E&P spending.

The Transaction materially improves the Company’s debt maturity profile while still allowing PGS flexibility to pursue its deleveraging strategy without incurring excessive costs.

  • After the Transaction, $138 million of the TLB maturing in March 2024 will remain outstanding and be repaid at par value from cash flow and liquidity sources
  • The $50 million super senior loan maturing in March 2024 remains in place. The loan may be extended by one year at the Company’s discretion or alternatively be replaced by a revolving credit and guarantee facility of up to $75 million
  • The Bonds are callable after two years with a customary declining call premium profile

Early February PGS made a repayment of $83 million on its export credit financing (“ECF”) loans. The remaining balance of the ECF loans is $180 million gross (~$140 million net, if considering ~$40 million of restricted cash for debt service on the ECF loans).

The Bonds will carry a fixed interest of 13.5%. The total interest costs for the Company will be reduced following the Transaction as the Company will have significantly less debt. In addition, the interest on the remaining portion of the TLB is expected to be reduced by approximately 1% as a result of improved credit ratings and lower leverage. The Company remains committed to continue reducing its debt and thereby further reduce interest cost.  

PGS retains a strong liquidity reserve after the debt repayments.

DNB Markets, a part of DNB Bank ASA and Pareto Securities AS acted as joint bookrunners (the "Joint Bookrunners") for the issuance of the Bonds. Advokatfirmaet BAHR AS is acting as Norwegian counsel to the Company and Wikborg Rein Advokatfirma AS is acting as Norwegian counsel to the Joint Bookrunners and Nordic Trustee.


FOR DETAILS, CONTACT:
Bård Stenberg, VP IR & Corporate Communication
Mobile: +47 99 24 52 35

***
PGS ASA and its subsidiaries (“PGS” or “the Company”) is a fully integrated marine geophysical company that provides a broad range of seismic and reservoir services, including data acquisition, imaging, interpretation, and field evaluation. Our services are provided to the oil and gas industry, as well as to the broader and emerging new energy industries, including carbon storage and offshore wind. The Company operates on a worldwide basis with headquarters in Oslo, Norway and the PGS share is listed on the Oslo stock exchange (OSE: PGS). For more information on PGS visit www.pgs.com.

***

The information included herein contains certain forward-looking statements that address activities, events or developments that the Company expects, projects, believes or anticipates will or may occur in the future. These statements are based on various assumptions made by the Company, which are beyond its control and are subject to certain additional risks and uncertainties. The Company is subject to a large number of risk factors including but not limited to the demand for seismic services, the demand for data from our multi-client data library, the attractiveness of our technology, unpredictable changes in governmental regulations affecting our markets and extreme weather conditions. For a further description of other relevant risk factors we refer to our Annual Report for 2021. As a result of these and other risk factors, actual events and our actual results may differ materially from those indicated in or implied by such forward-looking statements. The reservation is also made that inaccuracies or mistakes may occur in the information given above about current status of the Company or its business. Any reliance on the information above is at the risk of the reader, and PGS disclaims any and all liability in this respect.

--END--


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Årsrapport 202223.3.2023 22:58:17 CET | pressemeddelelse

Selskabsmeddelelse nr. 2 – 2023 København, den 23. marts 2023 Årsrapport 2022 Bestyrelsen i NTR Holding A/S har i dag behandlet og godkendt Selskabets årsrapport for regnskabsåret 2022. Årsrapporten har følgende hovedpunkter: NTR Holding koncernens salg af Daniamant A/S og Daniamant Ltd. blev gennemført den 31. januar 2022. Hovedparten af provenuet fra salget af Daniamant er udbetalt som udbytte. NTR Holding A/S har således i 2022 udbetalt udbytte på i alt DKK 49 pr. aktie, svarende til et samlet udbytte på DKK 121 mio. Bestyrelsen foreslår, at der ikke udloddes yderligere udbytte for 2022. Koncernens resultat af primær drift udviser et underskud på DKK 2,5 mio. (DKK -1,9 mio. i 2021), hvilket er i overensstemmelse med de senest udmeldte resultatforventninger. Koncernens totalindkomst udgør DKK 1,1 mio. Egenkapitalen udgør DKK 12,9 mio., svarende til en indre værdi pr. aktie på DKK 5,2. Bestyrelsen vil fortsat sondere NTR Holding A/S’ strategiske muligheder, herunder for at kapitaliser

Millicom (Tigo) announces a change in the Nomination Committee ahead of the 2023 Annual General Meeting23.3.2023 22:40:00 CET | Press release

Millicom (Tigo) announces a change in the Nomination Committee ahead of the 2023 Annual General Meeting Luxembourg, March 23, 2023 – The Nomination Committee of Millicom International Cellular S.A. (“Millicom”) announces that Mr. Nicolas Jaeger appointed by Atlas Luxco S.àr.l., has joined the Nomination Committee of Millicom. On March 17, 2023, Atlas Luxco S.àr.l. reported that it holds a 20% shareholding in Millicom. On March 23, 2023 Mr. Nicolas Jaeger joined the Nomination Committee. The Nomination Committee comprises Jan Dworsky, appointed by Swedbank Robur Funds; Viktor Kockberg, appointed by Nordea Investment Funds; Staley Cates, appointed by Southeastern Asset Management, Gerardo Zamorano appointed by Brandes Investment Partners, and Nicolas Jaeger appointed by Atlas Luxco S.àr.l., as well as the Chairman of Millicom’s Board of Directors, José Antonio Ríos García. Information about the work of the Nomination Committee can be found on Millicom’s website. Shareholders wishing to p

GreenMobility issues warrants23.3.2023 22:40:00 CET | Press release

Company Announcement no. 121– 2023 Copenhagen, March23rd, 2023 GreenMobility issues warrants The Board of Directors of GreenMobility A/S S (“GreenMobility” or the “Company”), has today resolved to grant warrants in the Company for the purpose of: Ensuring that shareholders, the Executive Management and other management employees of the Company have the same interests, and that everyone makes a special effort for the value creation in the Company and its subsidiaries.Retaining the Executive Management and management employees of the Company.Granting warrants to the Board of Directors as authorized at the 2021 Annual General Meeting but not yet granted Warrants granted will generally be subject to the existing warrant programs as publicized in company announcement no. 41 on November 19th, 2019 and in company announcement no. 64 on September 29th 2020 with certain deviations. The total issuance of warrants is in accordance with the resolutions passed at the Annual General Meetings held on

Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results23.3.2023 22:00:00 CET | Press release

Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 full-year financial results on Thursday, March 30, 2023. Inventiva’s 2022 full-year financial results will be published on Wednesday, March 29, 2023 at 4:00 pm (New York), 10:00 pm (Paris). Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, onThursday, March 30, 2023, at8:00 am (New York)

Nyxoah Announces a $15 Million Private Placement Financing23.3.2023 21:05:00 CET | Press release

INSIDE INFORMATION REGULATED INFORMATION NyxoahAnnounces a $15 Million Private Placement Financing Mont-Saint-Guibert, Belgium – March 23, 2023, 9:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced a €13.35 million private placement financing from the sale of 2,047,544 new ordinary shares at a price per share of €6.52 (approximately U.S. $7.10 at current exchange rates), the closing price on Euronext Brussels on March 23, 2023. Gross proceeds total €13.35 million (approximately U.S. $15 million at current exchange rates) and will be used for general corporate purposes. The closing is expected to occur on or about March 30, 2023, subject to customary closing conditions. The private placement financing includes historical Nyxoah shareholders, notably ResMed and Robert Taub, Nyxoah’s Founde